Big capital and early innovation met this week in MedTech, with major financings in commercial-stage platforms and continued backing for emerging device and digital health companies. More details below.
Novanta announces $300M Private Placement
Pursuant to the terms of the securities purchase agreement, the investors agreed to purchase an aggregate of 2,142,857 Common Shares at a purchase price of $140.00 per share.
The private placement is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions.
Chair and CEO Matthijs Glastra
Last week’s tracker: CereVasc, Subtle Medical & more
CeQur closes $100M Series E to support mealtime insulin patch
The company plans to use the investment to expand its commercial operations, strengthen relationships with healthcare providers and diabetes specialists, and increase access to its technology.
The Series E financing comes as CeQur enters a major commercial growth phase.
President and CEO Bradley Paddock
GT Medical completes oversubscribed $100M Series E
Led by Viking Global Investors, the oversubscribed round included participation from existing investors, including MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures.
The funding follows a $53M Series D financing completed last year.
CEO Per Langoe
Kalogon raises $5.75M to make sitting healthier for all
The investment was led by Enable Ventures, with participation from Florida Opportunity Fund, Castellan Group and returning investors DeepWork Capital, Sawmill Angels and Black Opal.
The company will use the funds to expand globally, grow its engineering and commercial teams, and further develop its AI-enabled seating systems.
Founder and CEO Tim Balz
Nuwellis closes $6.0M Registered Public Offering
The public offering price per share of Common Stock and accompanying warrants is $0.30 per share and accompanying warrants, and the public offering price per pre-funded warrant and accompanying warrants is $0.2999 per pre-funded warrant and accompanying warrants.
Each pre-funded warrant has an exercise price of $0.0001 per pre-funded warrant, and is immediately exercisable until such pre-funded warrant is exercised in full.
CEO John Erb
Nanordica Medical secures €1.6M to advance antibiotic-free wound care technology
The funds will support clinical and regulatory progress for Nanordica’s Premotiv wound dressing. The company will also use the financing to complete its ongoing large clinical trial, secure CE marking, and prepare for the commercial launch of its antibiotic-free chronic wound treatment in Europe.
The round was led by 2C Ventures with support from Specialist VC, Superangel, Amalfi, the Health Founders syndicate, and the EstBAN syndicate.
Co-Founder and CEO Olesja Bondarenko
Aortyx raises €1.5M to support vascular medical technology development
With this financing, Avançsa joins Aortyx’s Series A financing round, which now exceeds €15M following the public holding’s investment.
The additional funding will enable Aortyx to advance the development and clinical validation of its bioabsorbable patch for the treatment of aortic tears, an innovative solution for a severe vascular condition.
Co-Founder and CEO Jordi Martorell
Integra secures $1.1M for expansion
The funding will support product delivery, market expansion, and development of the startup’s robotics platform.
The round was led by Finvolve and India Accelerator, with participation from the GrowthCap Venture Fund.
Co-Founder and CEO Abhit Kumar
Joyvié Health raises £771K to redesign continence underwear
The pre-seed round was backed by an Innovate UK grant alongside investments from HERmesa Angels, SyndicateRoom, and Lavender Ventures.
The funds will support a direct-to-consumer launch later this year and clinical pilots across care home, hospital, and home care settings.
Founder and CEO Zoe Robson
